Bayer’s Finerenone Hits Primary Endpoint in Phase III Heart Failure Trial

With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.

Scroll to Top